RIPK3 and breast carcinoma: Koo et al. have shown that genomic methylation adjacent to the transcriptional starting site leads to a decrease in RIP3 in breast cancer patients; moreover, this causes chemoresistance to cisplatin, camptothecin (CPT) and 5-fluorouracil (5-FU) [71].